Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer
Study Number: EA2201
This phase II trial investigates the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may kill more cancer cells.
Just in Time Trial
- Navigator Carrie, 309-243-3621 firstname.lastname@example.org
- Drea, 309-243-3626 email@example.com